TB-IRIS decreases the levels of several circulating inflammatory markers, including IL-6 and Th1/2/17 cytokines (IL-2, IL-3, IL-12, IL-15, and IL-17A) (Ravimohan et al., 2015). Here, IL2 is linked to tuberculosis.